Dr. Joel Cooper accepted to be new Medical Advisor to XVIVO perfusion

Dr. Joel Cooper became the first surgeon in the world to complete the first
successful lung transplant.  Dr. Cooper, who recently accepted an appointment to
become the Medical Advisor to XVIVO Perfusion, is an internationally recognized
surgeon and scientist renowned for his pioneering techniques and progress in the
treatment of lung diseases.
This year, the 6th of November, the medical field of transplantation celebrates
the 30th anniversary of the first successful lung transplantation performed by
Dr. Cooper and his surgical team at the University of Toronto. In 1983, November
7, the world´s first successful single-lung transplant operation was performed
at Toronto General Hospital by a team led by Dr. Joel Cooper. The patient lived
an active life for 6 years before passing away from kidney failure at the age of
64. Some years later Dr. Cooper also performed the world´s first successful
clinical double lung transplants in St Louis, Missouri, USA.

Dr. Cooper, who recently accepted an appointment to be the Medical Advisor to
XVIVO Perfusion, is an internationally recognized surgeon and scientist who has
dedicated his time and work in experimental and clinical lung transplantation.
He is known for his pioneering techniques and has received numerous honors and
prestigious awards over the years. Dr. Cooper is member of editorial boards,
author and coauthor of more than 400 peer-reviewed scientific articles. Besides
lung transplantation, Dr Cooper’s main clinical interests include general
thoracic surgery, lung volume reduction surgery for emphysema, myasthenia
gravis, gastro esophageal reflux, and esophageal cancer.

Dr. Cooper recently stepped down from his position as the Chief of the Division
of Thoracic Surgery at UPHS, Philadelphia, Pennsylvania, USA. Prior to Dr
Cooper´s position at UPHS, Dr. Cooper served as the Professor of Surgery and
Chief of the Division of Cardiothoracic Surgery at Washington University and
Barnes-Jewish Hospital in St. Louis and before that as Surgical Director of the
lung transplant group at Toronto General Hospital.

Dr. Cooper will be working as Medical Advisor for XVIVO, specifically in
Research and Development for new products and solutions in lung transplantation.

“We are very excited that Dr. Cooper accepted the position of Medical Advisor
for XVIVO. Dr. Cooper’s pioneering work in developing clinical lung
transplantation to what it is today was indeed ground breaking. Dr. Cooper’s
work has always been in the forefront both in terms of basic and clinical
research and development and many of today’s leaders have been fostered under
his supervision. Since Dr. Cooper has great knowledge, experience and contacts
in the field of thoracic surgery we are very excited to have the opportunity to
develop a close relationship with him and are certain that it will help XVIVO to
further develop the company’s core technology – Ex Vivo perfusion of organs at
normothermic temperatures.” says Dr. Magnus Nilsson, CEO, XVIVO Perfusion.

October 25, 2013
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, tel: +46 31 788 21 59, e-mail:
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

Xvivo Perfusion is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication
on October 25, 2013 at 10:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com